Evidence map›Paper›PMID 35099715›Full record

ArticleJournal of cardiovascular translational research2022

Selective Enhancement of Swine Myocardium with a Novel Ultrasound Enhancing Agent During Transthoracic Echocardiography.

Michael Cimorelli, Michael A Flynn, Brett Angel, Emily Reimold, Sahil S Banka, Benjamin Andrien, Aaron Fafarman, Richard Huneke, Andrew Kohut, Steven Wrenn

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Michael CimorelliChemical and Biological Engineering, Drexel University, Philadelphia, PA, USA. michael.j.cimorelli@gmail.com.ORCID 0000-0003-0102-0006
Michael A FlynnChemical and Biological Engineering, Drexel University, Philadelphia, PA, USA.
Brett AngelCardiology, Drexel University College of Medicine, Philadelphia, PA, USA.
Emily ReimoldUniversity Laboratory Animal Resources, Drexel University College of Medicine, Philadelphia, PA, USA.
Sahil S BankaCardiology, Einstein Medical Center, Philadelphia, PA, USA.
Benjamin AndrienChemical and Biological Engineering, Drexel University, Philadelphia, PA, USA.
Aaron FafarmanChemical and Biological Engineering, Drexel University, Philadelphia, PA, USA.
Richard HunekeUniversity Laboratory Animal Resources, Drexel University College of Medicine, Philadelphia, PA, USA.
Andrew KohutCardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Steven WrennChemical and Biological Engineering, Drexel University, Philadelphia, PA, USA. michael.j.cimorelli@gmail.com.
Drexel University · USEinstein Medical Center Philadelphia · USPhoenixville Hospital · USUniversity of Pennsylvania · US

Funding

Innovative Voltage-Activated Ultrasound Imaging Agent for Selective Myocardial EnhancementR44HL156733 · NHLBI · SONNEST, INC. · PI CIMORELLI, MICHAEL, WRENN, STEVEN P · 2021 to 2022
$1.7M
NHLBI NIH HHS R44 HL156733U.S. Department of Education P2000 A150240
6 · The paper itself

Abstract

Ultrasound enhancing agents are approved to delineate the endocardial border and opacify the left ventricle cavity (LVC). We present a nested phase change agent (NPCA) designed to enable selective myocardial enhancement without enhancing the LVC by employing a dual-activation mechanism dependent on sufficient ultrasound intensity and the microenvironment of the myocardium. Swine received bolus injections of NPCA while echocardiograms were collected and processed to determine background-subtracted acoustic intensities (AI) in the LVC and septal myocardium. At mechanical index (MI) ≥ 0.8, the NPCA enhanced the myocardium selectively (p < 0.001) while the LVC remained at baseline AI. A 5-mL bolus of NPCA enhanced swine myocardium and enhancement persisted for > 5 min at 1.4 MI, while hemodynamics and EKG remained normal. Our findings demonstrate that the NPCA enhances swine myocardium selectively without enhancing the LVC. The NPCA could have utility for functional and structural echocardiographic studies with clinical ultrasound using standard settings.

Indexed as

Contrast MediaEchocardiographyAnimalsHeart VentriclesMyocardiumSwineContrast MediaMyocardial contrast echocardiographyMyocardial perfusion imagingNested phase change agentSelective myocardial enhancementUltrasound enhancing agent

Identifiers

PMID35099715
PMCPMC9339037
OpenAlexW4210441148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.